Authors
Lauren E.W. Olsho, PhD, Laura J. Edwards, MPH, Brian Sokol, MSPA, Abt Global; Sarang K. Yoon, DO, MOH, Kurt T. Hegmann, MD, MPH, Matthew S. Thiese, PhD, MSPH, University of Utah Health; Jefferey L. Burgess, MD, MS, MPH, Katherine Ellingson, PhD, Karen Lutrick, PhD, University of Arizona; Alberto J. Caban-Martinez, DO, PhD, Natasha Schaefer Solle, PhD, John M. Jones, B.S., University of Miami; Harmony Tyner, MD, St. Luke’s Regional Health Care System (Duluth, MN); Manjusha Gaglani, MBBS, Kayan Dunnigan, MPH Spencer Rose, B.S. Baylor Scott & White Health; Allison Naleway, PhD, Holly Groom, MPH, Jennifer Kuntz, PhD, Kaiser Permanente Northwest; Ashley L. Fowlkes, ScD, Mark G. Thompson, PhD, Young M. Yoo, MSPH, Centers for Disease Control and Prevention (CDC)
In a letter to the editor of the New England Journal of Medicine, researchers from Abt Global and their partners reported that a study of essential and frontline workers showed that three doses of COVID-19 vaccine are more effective than two. The vaccines are less effective against Omicron than against the Delta variant but are effective against both.
The study for the Centers for Disease Control and Prevention (CDC) involved 3,241 essential and frontline workers who sent in nasal swabs weekly from August 26, 2021 until January 22, 2022, regardless of whether they had symptoms. Effectiveness against the Delta variant was 65 percent after two doses and 91 percent after three. The results were similar to a study in which participants received medical care because they had symptoms.
Vaccine effectiveness against Omicron infection for three doses (60 percent) was higher than for two doses (46 percent), but still substantially lower than three-dose effectiveness against Omicron reported elsewhere where individuals sought medical attention for their symptoms (82-90 percent). Lower effectiveness against mild or asymptomatic Omicron infection dovetails with data suggesting the Omicron variant is less severe. The results show continued effectiveness against clinically severe outcomes related to both variants.
The authors’ findings and conclusions do not necessarily represent the CDC’s views.
Read More
COVID-19 in North America
Rural Communities Opioid Response Program (RCORP) Evaluation
Abt supports HRSA’s rural opioid response by evaluating RCORP grants, strengthening reporting quality, and guiding targeted support for communities.
Where Data Meets Discovery: A One Health Conversation with Adam Schaefer
Abt's Adam Schaefer joins Dr. Ginger Dixon on One Health Wednesdays to explore the science, systems, and leadership driving meaningful progress in One Health research.
Potomac Officers Club AI Summit 2026
Abt delivers AI that agencies can use now, mission-ready solutions that support responsible adoption, operational fit, and measurable results.
CMS Quality Conference 2026
We combine deep expertise in policy and data with advanced analytics and business intelligence tools to help CMS programs achieve maximum performance.